 |
In this case study, like many top 10 and global pharma companies, an H1 client needed to diversify both its patient outreach and site investigator profiles for upcoming trials. The company had kicked off a new cross-enterprise focus on diversifying trial site principal investigators (PIs) and clinical trial site profiling. To support ongoing therapy development, the company was looking to gain a holistic view of potential trialists to be able to best profile and identify principal investigators who fit the organization’s diversity and inclusion strategic business needs for systemic lupus erythematosus (SLE) in the U.S. H1 used a tech-first, data-driven, and cross-functional approach to provide a holistic understanding of trialists that best fit the ideal PI profile. Diversity metrics included: trial experience; relevant patient population D&I metrics; academic expertise; HCP historical performance, and HCP demographic information. Highlight of Findings: The client utilized H1’s Trial Landscape and PI Insite analysis to find:
Learn more by downloading the case study below. |
